New combo aims to crush 'Bad' cholesterol particle that other drugs miss

NCT ID NCT06496243

Recruiting now Disease control Sponsor: NewAmsterdam Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This 16-week study tests whether a daily pill (obicetrapib) plus a twice-monthly shot (evolocumab, sold as Repatha) can lower a fatty particle called lipoprotein(a) that raises heart disease risk. About 69 adults with mildly high cholesterol and elevated Lp(a) will take the pill alone for 8 weeks, then add the shot for another 8 weeks. The goal is to see if the combination works better than the pill alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: obicetrapib and evolocumab (Repatha)
What this could lead to: If successful, this could point toward a new combination treatment to lower Lp(a), a stubborn risk factor for heart disease.
What could go wrong: This is a small, early-phase study with only 69 people and no placebo group. Results may not hold up in larger trials, and the long-term benefits or risks are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias hyperlipidemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIAS

Contacts and locations

Locations

UPenn
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.